Clinical trial
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
Abstract
This open-label pilot study examines whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and effective for depression in people with Mild Cognitive Impairment (MCI) or early Alzheimer's Disease (AD). This study will also assess whether psilocybin may improve quality of life in those individuals.
Topics & conditions
Detected automatically by Psychedelic Commons from the title and abstract, not labels from the source. They may be incomplete.
Keywords
Psychedelic Commons aggregates metadata from open sources and links back to the original. Rights remain with the authors and publishers. Something wrong with this record? Report a problem.
Related research
ArticlePsilocybin
Association of Psilocybin Use in Adolescents with Major Depressive Episode
ArticlePsilocybin
Australia to prescribe MDMA and psilocybin for PTSD and depression in world first.
ArticlePsilocybin